dc.contributor
Institut Català de la Salut
dc.contributor
[Giovannoni G] Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. [Boyko A] Pirogov Russian National Research Medical University, Department of Neurology, Neurosurgery and Medical Genetics, Federal Center of Brain Research and Neurotechnologies, Moscow, Russia. [Correale J] Department of Neurology, FLENI Institute, Buenos Aires, Argentina. [Edan G] Department of Neurology, University Hospital of Rennes, Rennes, France. [Freedman MS] University of Ottawa, Department of Medicine and the Ottawa Hospital Research Institute, Ottawa, ON, Canada. [Montalban X] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Boyko, Alexey
dc.contributor.author
Correale, Jorge
dc.contributor.author
Edan, Gilles
dc.contributor.author
Freedman, Mark S
dc.contributor.author
Giovannoni, Gavin
dc.contributor.author
Montalban, Xavier
dc.date.issued
2023-12-19T09:18:47Z
dc.date.issued
2023-12-19T09:18:47Z
dc.identifier
Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, et al. A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study. Neurodegener Dis Manag. 2023 Oct;13(5):261–8.
dc.identifier
https://hdl.handle.net/11351/10717
dc.identifier
10.2217/nmt-2023-0018
dc.identifier
001042183200001
dc.description.abstract
Cladribina; Multiple sclerosis; Relapses
dc.description.abstract
Cladribina; Esclerosi múltiple; Recaigudes
dc.description.abstract
Cladribina; Esclerosis múltiple; Recaídas
dc.description.abstract
What is this summary about?
Previous studies have shown that people living with multiple sclerosis (MS) treated with cladribine tablets have fewer relapses (where new symptoms occur or existing symptoms get worse for 24 hours or more) and delayed disability progression (slowing down of the disease getting worse). The CLASSIC-MS study looked at the long-term effectiveness of treatment with cladribine tablets in people living with MS who had taken part in the original CLARITY and CLARITY Extension clinical studies.
What were the results?
Results showed that people treated with cladribine tablets maintained their mobility (the ability to move freely) for longer and experienced other positive effects long after their treatment ended, including being less likely to need further treatment for their MS.
What do the results mean?
The results obtained from CLASSIC-MS show that the benefits of taking cladribine tablets carry on even when patients stop taking the treatment.
dc.format
application/pdf
dc.publisher
Future Medicine
dc.relation
Neurodegenerative Disease Management;13(5)
dc.relation
https://doi.org/10.2217/nmt-2023-0018
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Esclerosi múltiple - Tractament
dc.subject
Medicaments immunosupressors - Ús terapèutic
dc.subject
DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Immunologic Factors::Immunosuppressive Agents
dc.subject
ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::efectos fisiológicos de los fármacos::factores inmunitarios::inmunosupresores
dc.title
A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
